, Volume 3, Issue 2, pp 264–275 | Cite as

Pediatric multiple sclerosis

  • Dorothée Chabas
  • Ari J. Green
  • Emmanuelle Waubant


Multiple sclerosis (MS) occurs at all ages of the pédiatric population. Childhood MS may represent up to 10% of all MS cases. Establishing the diagnosis of MS in a child is complicated by the limited diagnostic criteria and the possibility of significant clinical and magnetic resonance imaging (MRI) overlap with acute disseminated encephalomyelitis and other pediatric diseases. Although the clinical profile of MS appears similar to that seen in adults, several features may differ and specific issues arise in children. Sex ratios are different between young children with MS and adolescents— implicating a role for sex hormones in disease pathogenesis and/or modification of disease expression. Younger patients with MS are more likely to have seizures, brainstem, and cerebellar symptoms than adults. Children with MS may have fewer T2 hyperintense areas on MRI scans, therefore not meeting MRI criteria established for adults. It is possible that the pediatric MS course is more indolent than in adult patients but the disease may lead to significant disability at a younger age, e.g., while patients are students, young professionals, or want to start a family. There has been no controlled clinical trial in children with disease modifying therapies approved for adult MS due to the limited number of patients under the age of 18 years compared with the adult contingent. As a result, children are receiving adult therapies in an arbitrary manner and our understanding of pediatric treatment effect and tolerability is limited. Available data on tolerability of approved drugs for adults is reviewed.

Key Words

Multiple sclerosis acute disseminated encephalomyelitis pediatric treatments review 


  1. 1.
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis.N Engl J Med 343: 938–952, 2000.PubMedCrossRefGoogle Scholar
  2. 2.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey.Neurology 46: 907–911, 1996.PubMedCrossRefGoogle Scholar
  3. 3.
    Medaer R. Does the history of multiple sclerosis go back as far as the 14th century?Acta Neurol Scand 60: 189–192, 1979.PubMedCrossRefGoogle Scholar
  4. 4.
    Shaw CM, Alvord EC. Multiple sclerosis beginning in infancy.J Child Neurol 2: 252–256, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features.Acta Neurol Scand 86: 280–284, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.J Pediatr 144: 246–252, 2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.Ann Neurol 13: 227–231, 1983.PubMedCrossRefGoogle Scholar
  8. 8.
    McDonald WI, Compston A, Edan G, Goodkin D, Haltung HP, Lublin F et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.Ann Neurol 50: 121–127, 2001.PubMedCrossRefGoogle Scholar
  9. 9.
    Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis.Brain 113: 1477–1489, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort.Neurology 62: 806–808, 2004.PubMedCrossRefGoogle Scholar
  11. 11.
    Hauser SL, Bresnan MJ, Reinherz MJ, Weiner HL. Childhood multiple sclerosis: clinical features and demonstration of changes in T cell subsets with disease activity.Ann Neurol 11s: 463–468, 1982.CrossRefGoogle Scholar
  12. 12.
    Duquette P., Murray TJ, Pleines J, Ebers GC, Sadovnick D, Weldon P et al. Multiple sclerosis in childhood: clinical profile in 125 patients.J Pediatr 111: 359–363, 1987.PubMedCrossRefGoogle Scholar
  13. 13.
    Bauer HJ, Hanefeld F, Christen HJ. Multiple sclerosis in early childhood.Lancet 336: 1190, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases.Brain Dev 13: 410–416, 1991.PubMedCrossRefGoogle Scholar
  15. 15.
    Perniola T, Russo MG, Margari L, Buttiglione M, Simone IL. Multiple sclerosis in childhood: longitudinal study in 14 cases.Acta Neurol (Napoli) 13: 236–248, 1991.Google Scholar
  16. 16.
    Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G et al. Multiple sclerosis in childhood: clinical features of 149 cases.Mult Scler 3: 43–46, 1997.PubMedCrossRefGoogle Scholar
  17. 17.
    Pinhas-Hamiel O, Barak Y, Siev-Ner I, Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics.J Pediatr 132: 735–737, 1998.PubMedCrossRefGoogle Scholar
  18. 18.
    Ruggieri M., Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age.Neurology 53: 478–484, 1999.PubMedCrossRefGoogle Scholar
  19. 19.
    Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.Brain 123: 2407–2422, 2000.PubMedCrossRefGoogle Scholar
  20. 20.
    Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM, Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis: multiple sclerosis in children under 10 years of age.Neurol Sci 25 (Suppl 4): S326-S335, 2004.PubMedCrossRefGoogle Scholar
  21. 21.
    Ghezzi A. Childhood-juvenile multiple sclerosis: clinical characteristics and treatment.Expert Rev Neurother 5: 403–411, 2005.PubMedCrossRefGoogle Scholar
  22. 22.
    Rose AS, Ellison GW, Myers LW, Tourtelotte WW. Criteria for the clinical diagnosis of multiple sclerosis.Neurology 26: 20–22. 1976.PubMedCrossRefGoogle Scholar
  23. 23.
    Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease?Neurol Sci 25 (Suppl 4): S323-S325, 2004.PubMedCrossRefGoogle Scholar
  24. 24.
    Ghezzi A. Clinical characteristics of multiple sclerosis with early onset.Neurol Sci 25: S336-S339, 2004.PubMedCrossRefGoogle Scholar
  25. 25.
    Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.Ann Neurol 47: 707–717, 2000.PubMedCrossRefGoogle Scholar
  26. 26.
    Banwell B, Kennedy J, Krupp L, Bar-Or A, Tenembaum S, Belman A et al. Clinical and demographic features of pediatric MS: preliminary data from a multinational collaborative study.Neurology (Suppl 5) 62: A230, 2004.Google Scholar
  27. 27.
    Cole GF., Auchterlonie LA, Best PV. Very early onset multiple sclerosis.Dev Med Child Neurol 37: 667–672, 2005.CrossRefGoogle Scholar
  28. 28.
    Banwell BL. Anderson PE. The cognitive burden of multiple sclerosis in children.Neurology 64: 891–894, 2005.PubMedCrossRefGoogle Scholar
  29. 29.
    MacAllister WS, Belman AL, Milazzo M, Weisbrot DM, Christodoulou C, Scherl WF et al. Cognitive functioning in children and adolescents with multiple sclerosis.Neurology 64: 1422–1425, 2005.PubMedCrossRefGoogle Scholar
  30. 30.
    Hahn CD., Miles BS, Macgregor DL, Blaser SI, Banwell BL, Hetherington CR. Neurocognitive outcome after acute disseminated encephalomyelitis.Pediatr Neurol 29: 117–123, 2003.PubMedCrossRefGoogle Scholar
  31. 31.
    Baoxun ZDL, Weiming H, Xiugun L, Shihe L, Yinchang Y, Sinmei J et al. MS in China: a clinical study of 256 cases. In: Multiple Sclerosis East and West (Kuroiwa LKY, ed), pp 71–81. Fukuoka, Japan: Kyushu University Press, 1982.Google Scholar
  32. 32.
    Higa H, Toyonaga K, Nishihara T, Sakugawa H, Ikuta F. MS in Okinawa. In: Multiple Sclerosis East and West (Kuroiwa LKY, ed), pp 49–56. Fukuoka, Japan: Kyushu University Press, 1982.Google Scholar
  33. 33.
    Hung TP. MS in Taiwan: a reappraisal. In: Multiple Sclerosis East and West (Kuroiwa LKY, ed), pp 83–96. Fukuoka, Japan: Kyushu University Press, 1982.Google Scholar
  34. 34.
    Kim SW, Kim SK. Multiple sclerosis in Busan Korea: clinical features and prevalence. In: Multiple Sclerosis East and West (Kuroiwa LKY, ed), pp 57–80. Fukuoka, Japan: Kyushu University Press, 1982.Google Scholar
  35. 35.
    Shiraishi K, Higuchi Yozawa K, Hao Q, Saida T. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan.Brain Dev 27: 224–227, 2005.PubMedCrossRefGoogle Scholar
  36. 36.
    Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-bom children of immigrants from the Indian subcontinent, Africa and the West Indies.J Neurol Neurosurg Psychiatry 53: 906–911, 1990.PubMedCrossRefGoogle Scholar
  37. 37.
    Zelnik N., Gale AD, Shelbume SA Jr. Multiple sclerosis in black children.J Child Neurol 6: 53–57, 1991.PubMedCrossRefGoogle Scholar
  38. 38.
    Mikaeloff Y, Actamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, et al.: MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood.Brain 127: 1942–1947, 2004.PubMedCrossRefGoogle Scholar
  39. 39.
    Triulzi F, Scotti G. Differential diagnosis of multiple sclerosis: contribution of magnetic resonance techniques.J Neurol Neurosurg Psychiatry 64 (Suppl 1): S6-S14, 1998.PubMedGoogle Scholar
  40. 40.
    Hynson JL., Komberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children.Neurology 56: 1308–1312. 2001.PubMedCrossRefGoogle Scholar
  41. 41.
    Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis.Neurology 63: 1966–1967, 2004.PubMedCrossRefGoogle Scholar
  42. 42.
    Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis.JAMA 291: 1875–1879, 2004.PubMedCrossRefGoogle Scholar
  43. 43.
    Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review.J Neurol Sci 160: 16–25, 1998.PubMedCrossRefGoogle Scholar
  44. 44.
    Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.J Neurol 247: 435–442, 2000.PubMedCrossRefGoogle Scholar
  45. 45.
    Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.Neurology 58: 169–178, 2002.PubMedCrossRefGoogle Scholar
  46. 46.
    Beck RW. The optic neuritis treatment trial: three-year follow-up results.Arch Ophthalmol 113: 136–137, 1995.PubMedCrossRefGoogle Scholar
  47. 47.
    Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.Neurology 50: 1833–1836, 1998.PubMedCrossRefGoogle Scholar
  48. 48.
    Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations.Mult Scler 6: 267–273, 2000.PubMedGoogle Scholar
  49. 49.
    Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.Ann Neurol 46: 878–886, 1999.PubMedCrossRefGoogle Scholar
  50. 50.
    Takahashi I, Sawaishi Y, Takeda O, Enoki M, Takada G. Childhood multiple sclerosis treated with plasmapheresis.Pediatr Neurol 17: 83–87, 1997.PubMedCrossRefGoogle Scholar
  51. 51.
    Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis.Clin Neuropharmacol 21: 258–261, 1998.PubMedGoogle Scholar
  52. 52.
    Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis.Pediatr Neurol 21: 583–586, 1999.PubMedCrossRefGoogle Scholar
  53. 53.
    Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment.Brain Dev 21: 279–282, 1999.PubMedCrossRefGoogle Scholar
  54. 54.
    Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis.J Neurol Sci 165: 56–61, 1999.PubMedCrossRefGoogle Scholar
  55. 55.
    Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin.Neurology 54: 1370–1372, 2000.PubMedCrossRefGoogle Scholar
  56. 56.
    Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.Neurology 56: 1514–1522, 2001.PubMedCrossRefGoogle Scholar
  57. 57.
    Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.Neurology 63: 2028–2033, 2004.PubMedCrossRefGoogle Scholar
  58. 58.
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology 43: 655–661, 1993.CrossRefGoogle Scholar
  59. 59.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.Neurology 45: 1268–1276. 1995.PubMedCrossRefGoogle Scholar
  60. 60.
    Jacobs LD, Cookfair DL, Rudick RA, Hemdon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).Ann Neurol 39: 285–294, 1996.PubMedCrossRefGoogle Scholar
  61. 61.
    PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.Lancet 352: 1498–1504, 1998.CrossRefGoogle Scholar
  62. 62.
    Comi G, Filippi M, Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.Ann Neurol 49: 290–297, 2001.PubMedCrossRefGoogle Scholar
  63. 63.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.N Engl J Med 343: 898–904, 2000.PubMedCrossRefGoogle Scholar
  64. 64.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.Lancet 357: 1576–1582, 2001.PubMedCrossRefGoogle Scholar
  65. 65.
    PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.Neurology 56: 1628–1636, 2001.CrossRefGoogle Scholar
  66. 66.
    Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.Lancet 360: 2018–2025, 2002.PubMedCrossRefGoogle Scholar
  67. 67.
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease.N Engl J Med 28: 362–368, 2005.CrossRefGoogle Scholar
  68. 68.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.N Engl J Med 28: 369–374, 2005.CrossRefGoogle Scholar
  69. 69.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.N Engl J Med 353: 375–381, 2005.PubMedCrossRefGoogle Scholar
  70. 70.
    Miller DH, Khan OA, Sheremata WA, Blimhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med 348: 15–23, 2003.PubMedCrossRefGoogle Scholar
  71. 71.
    Polman C, O’Connor P, Havrdova E, et al. Clinical results from AFFIRM: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing remitting multiples sclerosis (MS).Neurology 64 (Suppl 1): A146, 2005.Google Scholar
  72. 72.
    O’Connor P, Havrdova E, Hutchinson M, et al. Safety, tolerability and immunogenicity of natalizumab: results from the AFFIRM trial.Neurology 64 (Suppl 1): A146, 2005.Google Scholar
  73. 73.
    Miller D, O’Connor P, Havrdova E, et al. The efficacy of natalizumab on magnetic resonance imaging measures in patients with relapsing remitting multiple sclerosis: results from the AFFIRM trial.Neurology 64 (Suppl 1): A146, 2005.Google Scholar
  74. 74.
    Rudick R, Stuart W, Calabresi P, et al. SENTINEL: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab, when added to intramuscular interferon beta-1a, in patients with relapsing multiple sclerosis. One year clinical and MRI results.Neurology 64 (Suppl 1): A276, 2005.Google Scholar
  75. 75.
    Calabresi P, Stuart W, Confavreux C, et al. Safety and tolerability of natalizumab: results from the SENTINEL study.Neurology 64 (Suppl 1): A277, 2005.Google Scholar
  76. 76.
    Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.Neurology 57: 1969–1975, 2001.PubMedCrossRefGoogle Scholar
  77. 77.
    Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.Neurology 56: 1505–1513, 2001.PubMedCrossRefGoogle Scholar
  78. 78.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results.Neurology 56: 1496–1504, 2001.CrossRefGoogle Scholar
  79. 79.
    Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.Neurology 59: 679–687, 2002.PubMedCrossRefGoogle Scholar
  80. 80.
    Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.Neurology 60: 44–51, 2003.PubMedCrossRefGoogle Scholar
  81. 81.
    Kita M, Cohen J, Fox B et al. A phase II trial of mitoxantrone in patients with primary progressive MS: an exploratory, randomized, controlled trial.Neurology 62 (Suppl 5): A99, 2004.Google Scholar
  82. 82.
    Wolinsky J, Pardo L, Stark Y et al. Effect of glatiramer acetate on primary progressive multiple sclerosis: initial analysis of the completed PROMiSe trial.Neurology 62 (Suppl 5): A97, 2004.Google Scholar
  83. 83.
    Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.Lancet 364: 1149–1156, 2004.PubMedCrossRefGoogle Scholar
  84. 84.
    Tenmbaum S, Banwell B, Boiko A et al. Treatment of childhood and adolescent multiple sclerosis with interferon beta-1b.Neurology 64 (Suppl 1): A384, 2005.Google Scholar
  85. 85.
    Actams AB, Tyor WR, Holden KR. Interferon beta-1b and childhood multiple sclerosis.Pediatr Neurol 21: 481–483, 1999.CrossRefGoogle Scholar
  86. 86.
    Schilling S, Haertel C, Spemer J. Follow-up of interferon beta-1b treatment in patients with secondary progressive multiple sclerosis.Neuropediatrics 33: A31, 2002.Google Scholar
  87. 87.
    Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J et al. Interferon beta-1a in children with multiple sclerosis is well tolerated.Neuropediatrics 32: 211–213, 2001.PubMedCrossRefGoogle Scholar
  88. 88.
    Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.J Pediatr 139: 443–446, 2001.PubMedCrossRefGoogle Scholar
  89. 89.
    Ghezzi A, Ruggieri M, Trojano M, Filippi M. Italian studies on early-onset multiple sclerosis: the present and the future.Neurol Sci 25 (Suppl 4): S346-S349, 2004.PubMedCrossRefGoogle Scholar
  90. 90.
    Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.Neurology 64: 888–890, 2005.PubMedCrossRefGoogle Scholar
  91. 91.
    Tenembaum S, Segura M. Interferon beta-1a is effective and well tolerated in paediatric patients: results of a 6-year study.Multiple Scler (in press).Google Scholar
  92. 92.
    Etheridge LJ, Beverley DW, Feme C, McManus E. The use of interferon beta in relapsing-remitting multiple sclerosis.Arch Dis Child 89: 789–791, 2004.PubMedCrossRefGoogle Scholar
  93. 93.
    Komek B, Bernert G, Balassy C, Geldner J, Rayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.Neuropediatrics 34: 120–126, 2003.CrossRefGoogle Scholar
  94. 94.
    Krupp LB, Macallister WS. Treatment of pediatric multiple slerosis.Curr Treat Options Neurol 7: 191–199, 2005.PubMedCrossRefGoogle Scholar
  95. 95.
    Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS.Neurology 59: 802–808, 2002.PubMedCrossRefGoogle Scholar
  96. 96.
    Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group: every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).Lancet 359: 1453–1460, 2002.PubMedCrossRefGoogle Scholar
  97. 97.
    Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P et al. EVIDENCE Study Group. Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.Neurology 59: 1496–1506, 2002.PubMedCrossRefGoogle Scholar
  98. 98.
    PRISMS Study Group. Francis GS, Rice GP, Alsop JC, Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.Neurology 65: 48–55, 2005.PubMedCrossRefGoogle Scholar
  99. 99.
    Banwell B. Treatment of children and adolescents with multiple sclerosis.Expert Rev Neurother 5: 391–401, 2005.PubMedCrossRefGoogle Scholar
  100. 100.
    Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis.Lancet 349: 589–593, 1997.PubMedCrossRefGoogle Scholar
  101. 101.
    Achiron A, Gabbay U, Gilad R., Hassin-Baer S, Barak Y, Gornish M et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses.Neurology 50: 398–402, 1998.PubMedCrossRefGoogle Scholar
  102. 102.
    Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.Neurology 50: 1273–1281, 1998.PubMedCrossRefGoogle Scholar
  103. 103.
    Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis.Neurology 41: 20–25, 1991.PubMedCrossRefGoogle Scholar
  104. 104.
    Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K et al. Overview of azathioprine treatment in multiple sclerosis.Lancet 338: 1051–1055, 1991.PubMedCrossRefGoogle Scholar
  105. 105.
    Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis.Lancet 350: 261, 1997.PubMedCrossRefGoogle Scholar
  106. 106.
    Cavazzuti M, Merelli E, Tassone G, Mavilla L. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment: a retrospective study.Eur Neurol 38: 284–290, 1997.PubMedCrossRefGoogle Scholar
  107. 107.
    Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.N Engl J Med 308: 173–180, 1983.PubMedCrossRefGoogle Scholar
  108. 108.
    The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis.Lancet 337: 441–446. 1991.Google Scholar
  109. 109.
    Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.Neurology 43: 910–918, 1993.PubMedCrossRefGoogle Scholar
  110. 110.
    Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.J Neuroimmunol 99: 142–149, 1999.PubMedCrossRefGoogle Scholar
  111. 111.
    Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.Mult Scler 11: 573–582. 2005.PubMedCrossRefGoogle Scholar
  112. 112.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.Ann Neurol 37: 30–40, 1995.PubMedCrossRefGoogle Scholar
  113. 113.
    Goodkin DE, Rudick RA, VanderBrug Medendoip S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs.Neurology 47: 1153–1157, 1996.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2006

Authors and Affiliations

  • Dorothée Chabas
    • 1
  • Ari J. Green
    • 1
  • Emmanuelle Waubant
    • 1
  1. 1.Multiple Sclerosis CenterUniversity of California at San FranciscoSan Francisco

Personalised recommendations